Insider Trading February 24, 2026

Innospec Director Executes Options and Sells 1,030 Shares Worth $84,296

Milton C. Blackmore's February transactions leave him with 11,124 shares as the stock has slipped nearly 8% over the past week

By Marcus Reed IOSP
Innospec Director Executes Options and Sells 1,030 Shares Worth $84,296
IOSP

Director Milton C. Blackmore disclosed a set of transactions in Innospec Inc. (IOSP) during late February. On February 20, Blackmore sold 1,030 shares at $81.84 apiece for $84,296 and on the same day exercised options to acquire 1,030 shares at an exercise price of $44.18 for a reported total of $45,505. On February 23 he recorded the acquisition of 1,539 restricted stock units with a reported value of $0.00. Following these moves, Blackmore directly holds 11,124 shares. The company's shares trade at $79.30, down about 8% over the prior week. InvestingPro analysis cited in the filing describes the specialty chemicals firm as valued at $1.96 billion, trading at a P/E of 17, with a dividend raised 12 consecutive years and a current yield of 2.19%.

Key Points

  • Milton C. Blackmore sold 1,030 Innospec shares on February 20 at $81.84 each, totaling $84,296.
  • On February 20 Blackmore exercised options to acquire 1,030 shares at $44.18, reported at $45,505; on February 23 he acquired 1,539 restricted stock units valued at $0.00.
  • Following the transactions Blackmore directly owns 11,124 shares; the stock trades at $79.30, down nearly 8% over the past week. Sectors potentially impacted include specialty chemicals and broader industrial/materials markets.

Director Milton C. Blackmore of Innospec Inc. (IOSP) disclosed multiple equity transactions recorded in filings with the Securities and Exchange Commission.

On February 20, Blackmore sold 1,030 shares of Innospec common stock at $81.84 per share, a transaction that totaled $84,296. The sale was reported while the stock was trading at $79.30, a price that represents a decline of nearly 8% over the prior week.

The same Form 4 filing shows Blackmore exercised stock options on February 20 to acquire 1,030 shares at an option price of $44.18, for a reported total value of $45,505. A few days later, on February 23, he recorded the acquisition of 1,539 restricted stock units, for which the filing lists a value of $0.00.

After completing these transactions, Blackmore is shown as directly owning 11,124 shares of Innospec common stock.


Company snapshot cited in filings

  • The specialty chemicals company is described as having a market value of $1.96 billion.
  • InvestingPro analysis referenced in the filing indicates the company trades at a price-to-earnings ratio of 17.
  • The firm has increased its dividend for 12 consecutive years and currently offers a 2.19% yield, per the same analysis.
  • InvestingPro is noted as providing access to more than 10 additional tips for IOSP investors.

Context and implications

The documents show a mix of selling, option exercise, and restricted unit grants in a short time window in February. The reported sale and the contemporaneous option exercise are disclosed alongside a share-price move that left the security trading below the sale price and down almost 8% over the prior week. The filings also include a note on the valuation and dividend record cited from InvestingPro.

Where the filings list a value of $0.00 for the restricted stock units, the filing itself provides that figure without additional explanatory detail.

Risks

  • Short-term share-price volatility - the stock has declined nearly 8% over the past week, which may signal price risk for current and prospective shareholders, particularly in the chemicals and materials sectors.
  • Unclear valuation of restricted stock units - the filing lists 1,539 RSUs with a value of $0.00, which presents an uncertainty in interpreting compensation-related disclosures affecting governance and shareholder dilution considerations in the industrials sector.
  • Reliance on third-party analysis - the InvestingPro assessment that the company appears undervalued is an analytical opinion cited in the filing; investors may face differing interpretations of valuation and dividend sustainability in the specialty chemicals market.

More from Insider Trading

ImmunityBio Director Sells $250,000 in Stock as Company Posts Strong ANKTIVA Revenue Gains Feb 24, 2026 Palantir CEO Disposes $65.9M of Class A Shares, Converts Class B Stock Amid Corporate Momentum Feb 24, 2026 Palantir Director Sells $43.7M in Class A Shares as Stock Trades Below Peak Levels Feb 24, 2026 ImmunityBio Director Executes $1.78M Stock Sales as ANKTIVA Revenue Accelerates Feb 24, 2026 KalVista CFO Disposes $27,506 in Stock as Company Posts Strong EKTERLY Launch Metrics Feb 24, 2026